GlassScriptPhysician profile
Ramesh Ragothaman
NPI 1356331482
$761.97
in general payments reported to CMS, 2019-2025
15 companies · $109 in 2025
The $109 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $71.55 · 2021: $153 · 2022: $96.74 · 2023: $83.45 · 2024: $101 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $292.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $229.99 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Pfizer INC. | $83.13 | 2019-2024 | |
| Kaleo, INC. | $70.73 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $64.25 | 2024-2025 | Zoryve |
| Sanofi Pasteur INC. | $63.59 | 2019-2023 | |
| Glaxosmithkline, LLC. | $40.67 | 2019-2021 | |
| Alk-Abello, INC | $36.64 | 2021-2025 | Neffy |
| Cranial Technologies, INC | $33.02 | 2020-2021 | |
| Seqirus USA INC | $27.27 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $24.39 | 2025 | Dojolvi |
| Hologic Sales and Service, LLC | $21.17 | 2024 | Aptima |
| Xeris Pharmaceuticals, INC. | $19.29 | 2021 | |
| Kyowa Kirin, INC. | $16.64 | 2023 | Crysvita |
| Cumberland Pharmaceuticals, INC. | $15.98 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.21 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Ragothaman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.